Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Equity Ratio (2016 - 2025)

Rocket Pharmaceuticals' Equity Ratio history spans 10 years, with the latest figure at 0.84 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 4.43% year-over-year to 0.84; the TTM value through Dec 2025 reached 0.84, down 4.43%, while the annual FY2025 figure was 0.84, 4.43% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.84 at Rocket Pharmaceuticals, down from 0.85 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q3 2021 and bottomed at 0.83 in Q1 2021.
  • The 5-year median for Equity Ratio is 0.88 (2022), against an average of 0.88.
  • The largest annual shift saw Equity Ratio rose 27.06% in 2021 before it decreased 7.31% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.91 in 2021, then decreased by 3.0% to 0.89 in 2022, then dropped by 1.99% to 0.87 in 2023, then rose by 0.93% to 0.88 in 2024, then dropped by 4.43% to 0.84 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Equity Ratio are 0.84 (Q4 2025), 0.85 (Q3 2025), and 0.84 (Q2 2025).